Johnson & Johnson Innovation – JJDC — 2022 Investments
3 investments dated 2022 · listed companies and verified rows first · show all
Pulmocide is a biopharmaceutical company developing inhaled therapies for difficult-to-treat respiratory diseases, currently focused on respiratory fungal infections such as pulmonary aspergillosis.
BiotechHealthtech
Pete Strong(Co-founder)Garth Rapeport(Co-founder)inKazuhiro Ito(Co-founder)inJohn Murray(Co-founder)inDavid Mantusin
Co-investorsAdjuvant CapitalF-Prime CapitalJeito CapitalLongwood FundSR One Capital ManagementSV Health Investors+2 more
Rondo Therapeutics is an immuno-oncology biopharmaceutical company developing bispecific/multispecific antibody therapeutics designed for tumor-selective targeting to treat solid tumors while sparing healthy tissue.
BiotechHealthtech
Shelley Force Aldred(Co-Founder & Chief Executive Officer)inNathan Trinklein(Co-Founder, President & CSO)inKatherine(Chief Development Officer)Thomas(Chief Medical Officer)
Co-investorsSV Health InvestorsCanaan PartnersNovo Holdings
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.